宫缩抑制剂用于胎膜早破性早产

Observation of the Tocolytic Therapy Appliance in Preterm Premature Rupture of the Membranes

目的：了解产前运用宫缩抑制剂对胎膜早破早产新生儿结局的影响。方法：回顾性分析118例小于35孕周胎膜早破性早产(PPROM)的临床资料。结果：33～34^(+6)周孕龄组新生儿1min Apgar评分＜7分的发生率、缺血缺氧性脑病(HIE)发生率及新生儿呼吸窘迫综合症(NRDS)发生率明显低于对照组。两组间比较有显著差异(P＜0．05)。28～32^(+6)周孕龄组新生儿的各项指标在治疗组与对照组间比较无显著差异(P＞0．05)。结论：33～34^(+6)周胎膜早破性早产孕妇产前用宫缩抑制剂能显著改善新生儿结局。对＜33孕周的胎膜早破性早产,宫缩抑制剂的治疗效果还有待进一步探讨。

Objective：To understand the impact of antenatal treatment with the tocolytic therapy on the neonatal outcome of preterm premature rupture of the membranes. Methods：The clinical data of 118 cases of preterm labor with PPROM were arm lyzed retrospectively. Results. The incidence of neonatal Apgar score in one minute〈7, HIE and NRDS in the treatment group was significantly lower than in the control group in 33-34^＋6 gestational age（P〈0. 05） All index about the neonatal outcome had no significant difference between 28-32^＋6 gestational age （P〉 0. 05 ）. Conclusion： Antenatal treatment with the tocolytic therapy could significant improve the neonatal outcome of premature rupture of the membranes within 33-34^＋6 gestational ages. Its effect on preterm neonatal of gestational age less than 33 is uncertain.